# Synklino

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/synklino-aps

- Industry: Biotechnology
- Headquarters: Charlottenlund, Denmark
- Website: www.synklino.com
- Total disclosed funding: $31M
- Latest round: Series A (Jun 8, 2022)
- Investors on record: 4

## About

Synklino ApS is a biotechnology firm specializing in innovative therapies aimed at preventing cytomegalovirus infections in organ transplant patients, enhancing their post-transplant quality of life and recovery outcomes.Founded in 2017 in Charlottenlund, Denmark, Synklino ApS focuses on combating cytomegalovirus (CMV) infections in transplant patients. The company was co-founded by Thomas Kledal, who has a history in the biotechnology sector. In June 2022, Synklino raised DKK 222 million in a Series A funding round led by PKA, with participation from Eir Ventures, Maj Invest Equity, and Vaekstfonden, bringing the total amount raised to DKK 222 million. The company has engaged in two significant deals to date, aiming to enhance its operational capacity in the biotech field.Synklino ApS is focused on developing innovative therapies designed to eradicate the risk of cytomegalovirus (CMV) infections in transplant patients. Their primary product, SYN002, aims to improve the outcomes and quality of life for organ transplant recipients by either treating the donor organ ex vivo before transplantation or addressing the infection in the recipient in vivo post-transplant. This dual approach targets the significant challenges posed by CMV, which can lead to severe complications, increased morbidity, and prolonged hospital stays for patients undergoing transplantation. Synklino's services are primarily aimed at healthcare providers involved in transplantations, including hospitals and transplant centers, primarily in Europe and North America, where the need for effective CMV interventions is critical.In the most recent financial year of 2020, Synklino reported zero revenue. However, for 2023, the company reported an EBITDA of DKK -9,918,064, indicating the financial challenges it faces in its operational activities as it advances its therapeutic development.Synklino ApS plans to utilize the DKK 222 million raised in its Series A funding round for the development of SYN002, its candidate therapy for treating Cytomegalovirus (CMV). The company aims to enhance its product offerings and expand its market presence, specifically targeting healthcare institutions across Europe and North America. These initiatives are expected to strengthen its position in the transplantation ecosystem, facilitating better patient outcomes and addressing critical health challenges associated with CMV.

## Funding rounds

- Series A, Jun 8, 2022, $31M — PKA, Maj Invest, Vaekstfonden, Eir Ventures
- Seed, Sep 29, 2020 — Vaekstfonden, Eir Ventures

## Investors

- Vaekstfonden (https://capitalatlas.ai/funds/vaekstfonden) — Seed, Series A
- Eir Ventures (https://capitalatlas.ai/funds/eir-ventures) — Seed, Series A
- PKA — Series A
- Maj Invest (https://capitalatlas.ai/funds/maj-invest) — Series A